Lyumjev ® ▼ (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Lyumjev Summary of Product Characteristics (SmPC)

Lyumjev® ▼ (insulin lispro): Treprostinil and Platelet Inhibition

In the absence of systemic exposure of treprostinil, no inhibitor effect on platelet function is expected after injection of Lyumjev.

Treprostinil - Platelet Inhibition

In the absence of systemic exposure, no inhibitor effect on platelet function is expected.1

The dose of 10 ng of treprostinil does not show detectable circulating levels, and no systemic effects are shown.1

In the formulation of Lyumjev, microdoses of treprostinil are used as an excipient to increase blood flow at the site of injection through localized vasodilation.2-4

The commercial formulation of Lyumjev contains 10 ng of treprostinil per unit of insulin lispro in a 100 unit/mL formulation.1

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Leohr J, Pratt E, Heilmann C, et al. Treprostinil causes local vasodilation is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetologia. 2017;60(suppl 1):S313. http://dx.doi.org/10.1007/s00125-017-4350-z

3. Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro formulation containing citrate and treprostinil demonstrates faster absorption and onset of insulin action in healthy subjects [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488

4. Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488

Glossary

treprostinil = Remodulin® (treprostinil) injection

URLi = ultra rapid lispro

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: July 19, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question